Do analysts rate OGI or ZYBT?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Organigram Global 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33 Zhengye Biotechnology 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable earnings and valuation, OGI or ZYBT?

Zhengye Biotechnology has lower revenue, but higher earnings than Organigram Global. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Organigram Global $185.07M 0.83 -$17.70M -$0.13 N/A Zhengye Biotechnology $116.36M 0.35 -$9.98M N/A N/A

Do analysts recommend ASRT or ZYBT?

Assertio currently has a consensus target price of $22.65, indicating a potential downside of 3.47%. Given Assertio's stronger consensus rating and higher probable upside, equities research analysts clearly believe Assertio is more favorable than Zhengye Biotechnology. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Assertio 1 Sell rating(s) 4 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.80 Zhengye Biotechnology 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger valuation & earnings, ASRT or ZYBT?

Zhengye Biotechnology has lower revenue, but higher earnings than Assertio. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Assertio $118.71M 1.28 -$30.38M -$5.69 N/A Zhengye Biotechnology $116.36M 0.35 -$9.98M N/A N/A

Does the media refer more to ASRT or ZYBT?

In the previous week, Assertio and Assertio both had 2 articles in the media. Assertio's average media sentiment score of 0.00 beat Zhengye Biotechnology's score of -0.27 indicating that Assertio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Assertio 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Zhengye Biotechnology 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer CRBP or ZYBT?

Corbus Pharmaceuticals presently has a consensus target price of $42.00, indicating a potential upside of 443.62%. Given Corbus Pharmaceuticals' stronger consensus rating and higher possible upside, research analysts clearly believe Corbus Pharmaceuticals is more favorable than Zhengye Biotechnology. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Corbus Pharmaceuticals 2 Sell rating(s) 0 Hold rating(s) 9 Buy rating(s) 1 Strong Buy rating(s) 2.75 Zhengye Biotechnology 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger valuation & earnings, CRBP or ZYBT?

Zhengye Biotechnology has higher revenue and earnings than Corbus Pharmaceuticals. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Corbus Pharmaceuticals N/A N/A -$78.54M -$5.82 N/A Zhengye Biotechnology $116.36M 0.35 -$9.98M N/A N/A

Is CRBP or ZYBT more profitable?

Zhengye Biotechnology's return on equity of 0.00% beat Corbus Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Corbus Pharmaceuticals N/A -70.89% -61.78% Zhengye Biotechnology N/A N/A N/A

Does the media favor CRBP or ZYBT?

In the previous week, Corbus Pharmaceuticals had 3 more articles in the media than Zhengye Biotechnology. MarketBeat recorded 5 mentions for Corbus Pharmaceuticals and 2 mentions for Zhengye Biotechnology. Corbus Pharmaceuticals' average media sentiment score of 0.64 beat Zhengye Biotechnology's score of -0.27 indicating that Corbus Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Corbus Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Zhengye Biotechnology 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate NRXP or ZYBT?

NRx Pharmaceuticals presently has a consensus target price of $38.25, suggesting a potential upside of 887.10%. Given NRx Pharmaceuticals' stronger consensus rating and higher probable upside, equities analysts clearly believe NRx Pharmaceuticals is more favorable than Zhengye Biotechnology. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score NRx Pharmaceuticals 1 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.50 Zhengye Biotechnology 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger valuation & earnings, NRXP or ZYBT?

Zhengye Biotechnology has higher revenue and earnings than NRx Pharmaceuticals. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio NRx Pharmaceuticals $1.23M 114.14 -$28.62M -$1.09 N/A Zhengye Biotechnology $116.36M 0.35 -$9.98M N/A N/A

Is NRXP or ZYBT more profitable?

Company Net Margins Return on Equity Return on Assets NRx Pharmaceuticals N/A N/A -202.92% Zhengye Biotechnology N/A N/A N/A

Does the media refer more to NRXP or ZYBT?

In the previous week, NRx Pharmaceuticals had 9 more articles in the media than Zhengye Biotechnology. MarketBeat recorded 11 mentions for NRx Pharmaceuticals and 2 mentions for Zhengye Biotechnology. NRx Pharmaceuticals' average media sentiment score of 0.37 beat Zhengye Biotechnology's score of -0.27 indicating that NRx Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NRx Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 8 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Zhengye Biotechnology 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend ZYBT or SPRB?

Spruce Biosciences has a consensus price target of $169.67, indicating a potential upside of 244.33%. Given Spruce Biosciences' stronger consensus rating and higher possible upside, analysts plainly believe Spruce Biosciences is more favorable than Zhengye Biotechnology. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Zhengye Biotechnology 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Spruce Biosciences 1 Sell rating(s) 2 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.56

Which has preferable earnings & valuation, ZYBT or SPRB?

Zhengye Biotechnology has higher revenue and earnings than Spruce Biosciences. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Zhengye Biotechnology $116.36M 0.35 -$9.98M N/A N/A Spruce Biosciences $4.91M 27.60 -$38.97M -$36.60 N/A

Is ZYBT or SPRB more profitable?

Zhengye Biotechnology's return on equity of 0.00% beat Spruce Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Zhengye Biotechnology N/A N/A N/A Spruce Biosciences N/A -155.40% -101.67%

Does the media prefer ZYBT or SPRB?

In the previous week, Spruce Biosciences had 5 more articles in the media than Zhengye Biotechnology. MarketBeat recorded 7 mentions for Spruce Biosciences and 2 mentions for Zhengye Biotechnology. Spruce Biosciences' average media sentiment score of 0.87 beat Zhengye Biotechnology's score of -0.27 indicating that Spruce Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Zhengye Biotechnology 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Spruce Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Zhengye Biotechnology (ZYBT) Competitors

$0.85 -0.01 (-1.62%)

As of 03:00 PM Eastern

Compare

ZYBT vs. OGI, ASRT, CRBP, NRXP, and SPRB

Should you buy Zhengye Biotechnology stock or one of its competitors? MarketBeat compares Zhengye Biotechnology with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Zhengye Biotechnology include Organigram Global (OGI), Assertio (ASRT), Corbus Pharmaceuticals (CRBP), NRx Pharmaceuticals (NRXP), and Spruce Biosciences (SPRB). These companies are all part of the "pharmaceutical products" industry.

How does Zhengye Biotechnology compare to Organigram Global?

Organigram Global (NASDAQ:OGI) and Zhengye Biotechnology (NASDAQ:ZYBT) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, risk, dividends, earnings, institutional ownership, analyst recommendations, valuation and media sentiment.

In the previous week, Zhengye Biotechnology had 2 more articles in the media than Organigram Global. MarketBeat recorded 2 mentions for Zhengye Biotechnology and 0 mentions for Organigram Global. Organigram Global's average media sentiment score of 0.00 beat Zhengye Biotechnology's score of -0.27 indicating that Organigram Global is being referred to more favorably in the media.

Company	Overall Sentiment
Organigram Global	Neutral
Zhengye Biotechnology	Neutral

Zhengye Biotechnology has lower revenue, but higher earnings than Organigram Global.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Organigram Global	$185.07M	0.83	-$17.70M	-$0.13	N/A
Zhengye Biotechnology	$116.36M	0.35	-$9.98M	N/A	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Organigram Global	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Zhengye Biotechnology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Organigram Global has a beta of 1.43, meaning that its share price is 43% more volatile than the broader market. Comparatively, Zhengye Biotechnology has a beta of -2.4, meaning that its share price is 340% less volatile than the broader market.

34.6% of Organigram Global shares are held by institutional investors. 0.1% of Organigram Global shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Zhengye Biotechnology has a net margin of 0.00% compared to Organigram Global's net margin of -9.22%. Zhengye Biotechnology's return on equity of 0.00% beat Organigram Global's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Organigram Global	-9.22%	-13.41%	-9.09%
Zhengye Biotechnology	N/A	N/A	N/A

Summary

Organigram Global beats Zhengye Biotechnology on 8 of the 13 factors compared between the two stocks.

How does Zhengye Biotechnology compare to Assertio?

Assertio (NASDAQ:ASRT) and Zhengye Biotechnology (NASDAQ:ZYBT) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, profitability, dividends, risk, earnings, institutional ownership, analyst recommendations and valuation.

49.0% of Assertio shares are owned by institutional investors. 5.7% of Assertio shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Zhengye Biotechnology has a net margin of 0.00% compared to Assertio's net margin of -34.94%. Zhengye Biotechnology's return on equity of 0.00% beat Assertio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Assertio	-34.94%	-38.72%	-13.32%
Zhengye Biotechnology	N/A	N/A	N/A

Assertio currently has a consensus target price of $22.65, indicating a potential downside of 3.47%. Given Assertio's stronger consensus rating and higher probable upside, equities research analysts clearly believe Assertio is more favorable than Zhengye Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Assertio	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.80
Zhengye Biotechnology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Assertio has a beta of 0.51, indicating that its stock price is 49% less volatile than the broader market. Comparatively, Zhengye Biotechnology has a beta of -2.4, indicating that its stock price is 340% less volatile than the broader market.

Zhengye Biotechnology has lower revenue, but higher earnings than Assertio.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Assertio	$118.71M	1.28	-$30.38M	-$5.69	N/A
Zhengye Biotechnology	$116.36M	0.35	-$9.98M	N/A	N/A

In the previous week, Assertio and Assertio both had 2 articles in the media. Assertio's average media sentiment score of 0.00 beat Zhengye Biotechnology's score of -0.27 indicating that Assertio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Assertio	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Zhengye Biotechnology	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Assertio beats Zhengye Biotechnology on 8 of the 12 factors compared between the two stocks.

How does Zhengye Biotechnology compare to Corbus Pharmaceuticals?

Corbus Pharmaceuticals (NASDAQ:CRBP) and Zhengye Biotechnology (NASDAQ:ZYBT) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, earnings, media sentiment, dividends, profitability, risk and institutional ownership.

Zhengye Biotechnology's return on equity of 0.00% beat Corbus Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Corbus Pharmaceuticals	N/A	-70.89%	-61.78%
Zhengye Biotechnology	N/A	N/A	N/A

Corbus Pharmaceuticals presently has a consensus target price of $42.00, indicating a potential upside of 443.62%. Given Corbus Pharmaceuticals' stronger consensus rating and higher possible upside, research analysts clearly believe Corbus Pharmaceuticals is more favorable than Zhengye Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Corbus Pharmaceuticals	2 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.75
Zhengye Biotechnology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Zhengye Biotechnology has higher revenue and earnings than Corbus Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Corbus Pharmaceuticals	N/A	N/A	-$78.54M	-$5.82	N/A
Zhengye Biotechnology	$116.36M	0.35	-$9.98M	N/A	N/A

In the previous week, Corbus Pharmaceuticals had 3 more articles in the media than Zhengye Biotechnology. MarketBeat recorded 5 mentions for Corbus Pharmaceuticals and 2 mentions for Zhengye Biotechnology. Corbus Pharmaceuticals' average media sentiment score of 0.64 beat Zhengye Biotechnology's score of -0.27 indicating that Corbus Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Corbus Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
Zhengye Biotechnology	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

64.6% of Corbus Pharmaceuticals shares are owned by institutional investors. 3.5% of Corbus Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Corbus Pharmaceuticals has a beta of 2.57, meaning that its share price is 157% more volatile than the broader market. Comparatively, Zhengye Biotechnology has a beta of -2.4, meaning that its share price is 340% less volatile than the broader market.

Summary

Corbus Pharmaceuticals beats Zhengye Biotechnology on 9 of the 13 factors compared between the two stocks.

How does Zhengye Biotechnology compare to NRx Pharmaceuticals?

NRx Pharmaceuticals (NASDAQ:NRXP) and Zhengye Biotechnology (NASDAQ:ZYBT) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, analyst recommendations, media sentiment, profitability, valuation, earnings, risk and institutional ownership.

Zhengye Biotechnology has higher revenue and earnings than NRx Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NRx Pharmaceuticals	$1.23M	114.14	-$28.62M	-$1.09	N/A
Zhengye Biotechnology	$116.36M	0.35	-$9.98M	N/A	N/A

Company	Net Margins	Return on Equity	Return on Assets
NRx Pharmaceuticals	N/A	N/A	-202.92%
Zhengye Biotechnology	N/A	N/A	N/A

4.3% of NRx Pharmaceuticals shares are held by institutional investors. 6.4% of NRx Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

NRx Pharmaceuticals presently has a consensus target price of $38.25, suggesting a potential upside of 887.10%. Given NRx Pharmaceuticals' stronger consensus rating and higher probable upside, equities analysts clearly believe NRx Pharmaceuticals is more favorable than Zhengye Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NRx Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
Zhengye Biotechnology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, NRx Pharmaceuticals had 9 more articles in the media than Zhengye Biotechnology. MarketBeat recorded 11 mentions for NRx Pharmaceuticals and 2 mentions for Zhengye Biotechnology. NRx Pharmaceuticals' average media sentiment score of 0.37 beat Zhengye Biotechnology's score of -0.27 indicating that NRx Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NRx Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	8 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Zhengye Biotechnology	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

NRx Pharmaceuticals has a beta of 2.14, meaning that its share price is 114% more volatile than the broader market. Comparatively, Zhengye Biotechnology has a beta of -2.4, meaning that its share price is 340% less volatile than the broader market.

Summary

NRx Pharmaceuticals beats Zhengye Biotechnology on 9 of the 12 factors compared between the two stocks.

How does Zhengye Biotechnology compare to Spruce Biosciences?

Zhengye Biotechnology (NASDAQ:ZYBT) and Spruce Biosciences (NASDAQ:SPRB) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, analyst recommendations, media sentiment, institutional ownership, risk, valuation, profitability and dividends.

Zhengye Biotechnology's return on equity of 0.00% beat Spruce Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zhengye Biotechnology	N/A	N/A	N/A
Spruce Biosciences	N/A	-155.40%	-101.67%

Zhengye Biotechnology has a beta of -2.4, meaning that its share price is 340% less volatile than the broader market. Comparatively, Spruce Biosciences has a beta of 3.12, meaning that its share price is 212% more volatile than the broader market.

Spruce Biosciences has a consensus price target of $169.67, indicating a potential upside of 244.33%. Given Spruce Biosciences' stronger consensus rating and higher possible upside, analysts plainly believe Spruce Biosciences is more favorable than Zhengye Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zhengye Biotechnology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Spruce Biosciences	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.56

Zhengye Biotechnology has higher revenue and earnings than Spruce Biosciences.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zhengye Biotechnology	$116.36M	0.35	-$9.98M	N/A	N/A
Spruce Biosciences	$4.91M	27.60	-$38.97M	-$36.60	N/A

91.7% of Spruce Biosciences shares are owned by institutional investors. 4.3% of Spruce Biosciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, Spruce Biosciences had 5 more articles in the media than Zhengye Biotechnology. MarketBeat recorded 7 mentions for Spruce Biosciences and 2 mentions for Zhengye Biotechnology. Spruce Biosciences' average media sentiment score of 0.87 beat Zhengye Biotechnology's score of -0.27 indicating that Spruce Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zhengye Biotechnology	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Spruce Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Spruce Biosciences beats Zhengye Biotechnology on 9 of the 13 factors compared between the two stocks.

Get Zhengye Biotechnology News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ZYBT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ZYBT vs. The Competition

Export

Metric	Zhengye Biotechnology	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$40.28M	$3.32B	$6.49B	$11.92B
Dividend Yield	N/A	2.31%	2.67%	5.58%
P/E Ratio	N/A	19.11	23.98	23.72
Price / Sales	0.35	305.35	531.00	116.36
Price / Cash	N/A	51.45	26.99	37.25
Price / Book	0.91	8.17	10.57	6.75
Net Income	-$9.98M	$23.83M	$3.56B	$337.25M
7 Day Performance	7.59%	-2.68%	-0.84%	-2.31%
1 Month Performance	-13.71%	2.38%	1.41%	1.62%
1 Year Performance	-83.53%	37.71%	21.44%	24.64%

Zhengye Biotechnology Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ZYBT Zhengye Biotechnology	0.52 of 5 stars	$0.85 -1.6%	N/A	-85.4%	$40.28M	$116.36M	N/A	278	Gap Down
OGI Organigram Global	0.4293 of 5 stars	$1.08 +1.9%	N/A	-20.7%	$152.03M	$185.07M	N/A	1,139
ASRT Assertio	1.77 of 5 stars	$23.45 -0.1%	$22.65 -3.4%	+136.0%	$151.49M	$118.71M	N/A	20
CRBP Corbus Pharmaceuticals	4.5317 of 5 stars	$8.00 +8.4%	$42.00 +425.0%	-18.1%	$148.24M	N/A	N/A	40	High Trading Volume
NRXP NRx Pharmaceuticals	2.6971 of 5 stars	$4.05 flat	$38.25 +844.4%	+32.4%	$146.73M	$1.23M	N/A	2	Analyst Downgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ZYBT) was last updated on 6/9/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Zhengye Biotechnology (ZYBT) Competitors

ZYBT vs. OGI, ASRT, CRBP, NRXP, and SPRB

How does Zhengye Biotechnology compare to Organigram Global?

Summary

How does Zhengye Biotechnology compare to Assertio?

Summary

How does Zhengye Biotechnology compare to Corbus Pharmaceuticals?

Summary

How does Zhengye Biotechnology compare to NRx Pharmaceuticals?

Summary

How does Zhengye Biotechnology compare to Spruce Biosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ZYBT vs. The Competition

Zhengye Biotechnology Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Zhengye Biotechnology (ZYBT) Competitors

ZYBT vs. OGI, ASRT, CRBP, NRXP, and SPRB

How does Zhengye Biotechnology compare to Organigram Global?

Does the media refer more to OGI or ZYBT?

Which has preferable earnings and valuation, OGI or ZYBT?

Do analysts rate OGI or ZYBT?

Which has more volatility & risk, OGI or ZYBT?

Do institutionals & insiders believe in OGI or ZYBT?

Is OGI or ZYBT more profitable?

Summary

How does Zhengye Biotechnology compare to Assertio?

Do institutionals and insiders have more ownership in ASRT or ZYBT?

Is ASRT or ZYBT more profitable?

Do analysts recommend ASRT or ZYBT?

Which has more volatility and risk, ASRT or ZYBT?

Which has stronger valuation & earnings, ASRT or ZYBT?

Does the media refer more to ASRT or ZYBT?

Summary

How does Zhengye Biotechnology compare to Corbus Pharmaceuticals?

Is CRBP or ZYBT more profitable?

Do analysts prefer CRBP or ZYBT?

Which has stronger valuation & earnings, CRBP or ZYBT?

Does the media favor CRBP or ZYBT?

Do institutionals and insiders have more ownership in CRBP or ZYBT?

Which has more volatility & risk, CRBP or ZYBT?

Summary

How does Zhengye Biotechnology compare to NRx Pharmaceuticals?

Which has stronger valuation & earnings, NRXP or ZYBT?

Is NRXP or ZYBT more profitable?

Do institutionals and insiders hold more shares of NRXP or ZYBT?

Do analysts rate NRXP or ZYBT?

Does the media refer more to NRXP or ZYBT?

Which has more risk & volatility, NRXP or ZYBT?

Summary

How does Zhengye Biotechnology compare to Spruce Biosciences?

Is ZYBT or SPRB more profitable?

Which has more risk & volatility, ZYBT or SPRB?

Do analysts recommend ZYBT or SPRB?

Which has preferable earnings & valuation, ZYBT or SPRB?

Do insiders & institutionals believe in ZYBT or SPRB?

Does the media prefer ZYBT or SPRB?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ZYBT vs. The Competition

Zhengye Biotechnology Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools